Compass Therapeutics Inc. Common Stock (CMPX)

FairStock Score: 25/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Compass Therapeutics is a clinical-stage oncology company. It has 39 employees, two antibody candidates, tovecimig and CTX-471, and no marketed product. In FY2024 it reported $850,000 of revenue and a net loss of $49.4 million. In FY2025 the net loss widened to $66.5 million, or $0.42 per diluted share, with no revenue reported. In the first half of fiscal 2026, losses continued: fiscal Q1 2026 had a net loss of $18.3 million, and fiscal Q2 2026 had a net loss of $25.2 million. That trajectory shows a company consuming capital to fund trials, not a business compounding owner earnings. A moat? Not yet. In biotechnology, a durable moat comes from approved products, patent protection, manufacturing, and reimbursement; none of that is in these figures. Financial health: D/E of 0.06 is low, and the FairStock Altman Z-Score of 21.13 looks strong, but trailing free cash flow is negative $56.4 million, a negative 5.9% FCF yield. FairStock's Piotroski F-Score is 0/9. Valuation: at the 2026-10-13 close of $0.86, market cap is $948.2 million. FairStock calculations put P/E at negative 2.20, EPS at -$0.39, P/B at 0.93, ROE at -56.66%, and ROCE at -33.03%. The stock trades below book value, which would interest Graham if the assets were stable and liquid, but a clinical-stage biotech's book value is mostly cash being spent. The 52-week range of $0.83-$6.88 shows how violently sentiment has moved. FairStock Score is 25/100 and the Lynch category is none, because losses occurred in each of the last four years. Without revenue, profits, or approved products, I see no margin of safety in earnings; any value depends on pipeline outcomes not present in the financials.

In plain English: Compass Therapeutics is a small clinical-stage cancer drug developer with 39 employees. It has no meaningful revenue, loses money, and its losses have grown, so the business is not yet proven. At 86 cents a share on 2026-10-13, it trades below its stated book value and far below its 52-week high, but without profits or approved products the price is speculative rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer